Evidence map›Paper›PMID 30188893›Full record

ArticlePLoS genetics2018

Whole exome sequencing of ENU-induced thrombosis modifier mutations in the mouse.

Kärt Tomberg, Randal J Westrick, Emilee N Kotnik, Audrey C Cleuren, David R Siemieniak, Guojing Zhu, Thomas L Saunders, David Ginsburg

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Suppressor mutations inGenome research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kärt TombergDepartment of Human Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.ORCID 0000-0002-6144-3601
Randal J WestrickDepartment of Biological Sciences and Center for Data Science and Big Data Analysis, Oakland University, Rochester, Michigan, United States of America.
Emilee N KotnikLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.ORCID 0000-0002-9229-3378
Audrey C CleurenLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.ORCID 0000-0003-1384-4651
David R SiemieniakLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.
Guojing ZhuLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.
Thomas L SaundersDepartment of Internal Medicine, Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.ORCID 0000-0003-2015-101X
David GinsburgDepartment of Human Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
University of Michigan · USHoward Hughes Medical Institute · USOakland University · US

Funding

TRANSGENIC MODELS FOR THE STUDY OF FACTOR V FUNCTIONP01HL057346 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAWRENCE, DANIEL A · 1997 to 2013
$19.9M
The Molecular Genetics of HemostasisR35HL135793 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GINSBURG, DAVID · 2017 to 2023
$4.1M
Thrombosuppressive mechanisms of novel mutants discovered through an ENU mutagenesis screenR01HL135035 · NHLBI · OAKLAND UNIVERSITY · PI WESTRICK, RANDAL J · 2017 to 2021
$1.9M
Identification of the genetic regulators of Plasminogen Activator Inhibitor-1R15HL133907 · NHLBI · OAKLAND UNIVERSITY · PI WESTRICK, RANDAL J · 2016 to 2016
$433k
NHLBI NIH HHS HHSN268201100037CNHLBI NIH HHS P01 HL057346NHLBI NIH HHS R01 HL135035NHLBI NIH HHS R15 HL133907NHLBI NIH HHS R35 HL135793
6 · The paper itself

Abstract

Although the Factor V Leiden (FVL) gene variant is the most prevalent genetic risk factor for venous thrombosis, only 10% of FVL carriers will experience such an event in their lifetime. To identify potential FVL modifier genes contributing to this incomplete penetrance, we took advantage of a perinatal synthetic lethal thrombosis phenotype in mice homozygous for FVL (F5L/L) and haploinsufficient for tissue factor pathway inhibitor (Tfpi+/-) to perform a sensitized dominant ENU mutagenesis screen. Linkage analysis conducted in the 3 largest pedigrees generated from the surviving F5L/L Tfpi+/- mice ('rescues') using ENU-induced coding variants as genetic markers was unsuccessful in identifying major suppressor loci. Whole exome sequencing was applied to DNA from 107 rescue mice to identify candidate genes enriched for ENU mutations. A total of 3,481 potentially deleterious candidate ENU variants were identified in 2,984 genes. After correcting for gene size and multiple testing, Arl6ip5 was identified as the most enriched gene, though not reaching genome-wide significance. Evaluation of CRISPR/Cas9 induced loss of function in the top 6 genes failed to demonstrate a clear rescue phenotype. However, a maternally inherited (not ENU-induced) de novo mutation (Plcb4R335Q) exhibited significant co-segregation with the rescue phenotype (p = 0.003) in the corresponding pedigree. Thrombosis suppression by heterozygous Plcb4 loss of function was confirmed through analysis of an independent, CRISPR/Cas9-induced Plcb4 mutation (p = 0.01).

Indexed as

AnimalsCarrier ProteinsDisease Models, AnimalEthylnitrosoureaExome SequencingFactor VFemaleGenetic Predisposition to DiseaseHeat-Shock ProteinsHumansKaplan-Meier EstimateLipoproteinsMaleMembrane Transport ProteinsMiceMice, Inbred C57BLArl6ip5 protein, mouseCarrier ProteinsEthylnitrosoureaFactor Vfactor V LeidenHeat-Shock Proteinslipoprotein-associated coagulation inhibitorLipoproteinsMembrane Transport ProteinsPhospholipase C betaPlcb4 protein, mouse

Identifiers

PMID30188893
PMCPMC6143275
OpenAlexW2949099637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.